XML 64 R49.htm IDEA: XBRL DOCUMENT v3.7.0.1
Fair Value Measurements - Additional Information (Detail)
 12 Months Ended
Jun. 10, 2014
shares
Dec. 31, 2016
USD ($)
CommercialTest
shares
Dec. 31, 2015
USD ($)
shares
Jun. 15, 2016
shares
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]        
Transfers between Level 1, Level 2 and Level 3 categories during the periods | $   $ 0 $ 0  
Warrants outstanding       1,002,507
Fair Value Measured Using - (Level 3) [Member]        
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]        
Warrants outstanding   2,978,087    
ImmuMetrix, Inc. [Member]        
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]        
Contingent obligation to issue common stock 911,364      
Milestone description   the milestone will be achieved if the Company completes 2,500 commercial tests involving the measurement of dd-cfDNA in organ transplant recipients in the United States no later than six years after the closing date of the acquisition.    
ImmuMetrix, Inc. [Member] | Contingent consideration [Member]        
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]        
Contingent obligation to issue common stock   227,845 227,845  
Number of commercial tests involving the measurement of cfDNA to be completed | CommercialTest   2,500    
Milestone description   The issuance will occur if the Company completes 2,500 commercial tests involving the measurement of dd-cfDNA in organ transplant recipients in the United States by June 10, 2020.    
Probability of the achievement   80.00% 65.00%